Search Results - "Vianna, Jessica C."

Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response by Pagnano, Katia B.B., Lopes, Ana Beatriz P., Miranda, Eliana C., Delamain, Márcia T., Duarte, Gislaine O., Rodrigues, Bruna R.V., Povoa, Valquiria M.O., Furlin, Graziele C.P., Vianna, Jessica C., Silva, Matheus A.S., De Souza, Carmino A, De Paula, Erich V

Get full text

B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line by Da Silva, Matheus Sebastian, Miranda, Eliana C, Delamain, Marcia Torresan, Duarte, Gislaine Oliveira, Vergilio, Bruna R, Lopes, Ana Beatriz Pascoal, Vianna, Jessica CN, De Souza, Carmino Antonio, De Paula, Erich Vinicius, Pagnano, Katia B

“…Introduction: The achievement of a deep and sustained molecular response after treatment with tyrosine kinase inhibitors (TKI) is one of the requirements for…”
Get full text

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials by Pagnano, Katia B, Seguro, Fernanda S, Miranda, Eliana C, Lopes, Ana Beatriz Pascoal, Abdo, Andre, Delamain, Marcia Torresan, Pereira, Thales, Duarte, Gislaine Borba, Santos, Fernanda Maria, Vianna, Jessica CN, Da Silva, Matheus Sebastian, Nardinelli, Luciana, Povoa, Valquiria, Pavan, Graziele, Vergilio, Bruna R, Rocha, Vanderson, Souza, Carmino Antonio, De Paula, Erich V, Bendit, Israel

“…Several trials have demonstrated the feasibility of discontinuation of tyrosine kinase inhibitors (TKI) treatment in chronic myeloid leukemia (CML) patients…”
Get full text